OmanTuberculosis profile
Population  2014 4.2 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.024 (0.015–0.035) 0.56 (0.36–0.82)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.02 (0.01–0.04)
Prevalence  (includes HIV+TB) 0.52 (0.22–0.94) 12 (5.1–22)
Incidence  (includes HIV+TB) 0.41 (0.36–0.46) 9.6 (8.4–11)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.11 (0.09–0.12)
         
Case detection, all forms (%) 88 (78–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2.6 (0.96–5.6) 0 (0–41)
MDR-TB cases among notified pulmonary
TB cases
6 (2–13) 0 (0–3)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 234   7
Pulmonary, clinically diagnosed 0   0
Extrapulmonary 116   1
       
Total new and relapse 358    
Previously treated, excluding relapses 0    
Total cases notified 358    
Among 358 new and relapse cases:
8 (2%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 271 (116%) 8 (100%) 279
Laboratory-confirmed RR-/MDR-TB cases     8
Patients started on MDR-TB treatment ***     8
TB/HIV 2014 Number (%)
TB patients with known HIV status 358 (100)
HIV-positive TB patients 3 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 3 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (96) 330
Previously treated cases, excluding relapse, registered in 2013   0
HIV-positive TB cases, all types, registered in 2013 (100) 5
RR-/MDR-TB cases started on second-line treatment in 2012 (83) 6
XDR-TB cases started on second-line treatment in 2012 (50) 2
Laboratories 2014  
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-04 Data: www.who.int/tb/data